Supplementary appendix_figures.docx (1.79 MB)
Download file

Supplementary Figures – Indirect Treatment Comparisons of Avapritinib versus Midostaurin for Patients with Advanced Systemic Mastocytosis

Download (1.79 MB)
figure
posted on 04.02.2022, 09:19 by Figshare Future Science GroupFigshare Future Science Group, Hollie Pilkington, Sarah Smith, Neil Roskell, Sergio Iannazzo

Figure A: PRISMA flow diagram

Figure B: Subgroup analyses for pooled EXPLORER and PATHFINDER – overall survival in the RAC-RE population

Figure C: Subgroup analyses for pooled EXPLORER and PATHFINDER – overall response rate in the RAC-RE population

Figure D: Subgroup analyses for pooled EXPLORER and PATHFINDER – complete remission rate in the RAC-RE population

Figure E: Kaplan–Meier of pooled avapritinib (safety) versus pooled midostaurin (FAS)

Figure F: Kaplan–Meier of PATHFINDER avapritinib (RAC-RE) versus pooled midostaurin (PEP)

Figure G: Kaplan–Meier of pooled avapritinib (RAC-RE, midostaurin-naïve) versus pooled midostaurin (PEP)

Figure H: Kaplan–Meier of pooled avapritinib (RAC-RE, 200 mg) versus pooled midostaurin (PEP)

Figure I: Overall survival results when number of C-findings is included as a matching variable

Figure J: Overall response rate and complete remission results when number of C-findings is included as a matching variable

Funding

Blueprint Medicines

History